The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years.
Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next-generation agent. The recent AXIS trial reported on axitinib's efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients.
Written by:
Grünwald V, Merseburger AS. Are you the author?
Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Reference: Onco Targets Ther. 2012;5:111-7.
doi: 10.2147/OTT.S23273
PubMed Abstract
PMID: 22787405
UroToday.com Renal Cancer Section
